To send content items to your account,
please confirm that you agree to abide by our usage policies.
If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account.
Find out more about sending content to .
To send content items to your Kindle, first ensure email@example.com
is added to your Approved Personal Document E-mail List under your Personal Document Settings
on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part
of your Kindle email address below.
Find out more about sending to your Kindle.
Note you can select to send to either the @free.kindle.com or @kindle.com variations.
‘@free.kindle.com’ emails are free but can only be sent to your device when it is connected to wi-fi.
‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.
Over recent decades the early management of acute stroke has changed dramatically and the early post-stroke period has been the focus of much research. With advances in pharmacotherapeutics, and on the basis of many randomized controlled trials, the potential interventions now available within the first 24–48 hours following acute stroke are numerous.
This chapter will present the evidence and best practice guidance for interventions during the first 24–48 hours following stroke, based upon the European Stroke Organisation Guidelines 2008 and the European Stroke Initiative recommendations for the management of intracranial hemorrhage [1,2]. For the purposes of this chapter, the interventions discussed will generally be limited to the initial 48 hours following ictus. Access to some of these therapies may not be universal and may be dictated by local availability at individual stroke units. As with other aspects of stroke care, however, close cooperation and inter-disciplinary communication are essential.
In respect of acute interventions, one of the most significant advances during the last two decades has been the introduction of intravenous thrombolysis as a standard therapy for a well-selected population of patients with acute ischemic stroke. At present, the only thrombolytic agent licensed in Europe for the treatment of ischemic stroke is recombinant-tissue plasminogen activator (rtPA), alteplase.
This chapter focuses on the epidemiology of oral anticoagulant therapy (OAT)-associated ICH, its pathophysiology, and treatment options based on the currently available data. One of the most common indications for OAT is to prevent stroke in patients with atrial fibrillation. Intracerebral hemorrhage is the deadliest form of stroke, with a mortality rate between 30% and 55%. The incidence and dynamics of hematoma expansion in OAT-ICH remain to be established. Current data suggest that the natural course of hematoma expansion in this group of patients is more prolonged as compared to spontaneous ICH. This may provide a longer time window for treatment of OAT-ICH. However, in OAT-ICH the underlying coagulopathy prolongs the time course of bleeding or rebleeding, and repeated dosing or a higher dose might be essential. The risk of thromboembolism that is associated with current hemostatic treatment strategies which aim to normalize coagulation is unknown.
Email your librarian or administrator to recommend adding this to your organisation's collection.